The FDA has recently admitted there is now major concern over another Pfizer product. It is now slapping a warning on a class of anti-inflammatory treatments called JAK inhibitors. “The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over,” Reuters reported on Friday, citing the drug manufacturers.
“The addition of the warning
on the labels follows the agency’s review of Pfizer’s Xeljanz after
initial results from a February trial showed an increased risk of
serious heart-related problems and cancer in some patients being treated
with the drug,” the report added..........To Read More.....
No comments:
Post a Comment